Literature DB >> 2559248

Estrone sulfate and sulfatase activity in human breast cancer and endometrial cancer.

K Naitoh1, H Honjo, T Yamamoto, M Urabe, Y Ogino, T Yasumura, T Nambara.   

Abstract

Estrone sulfate (E1-S) in the serum and tissues of patients with breast cancer or endometrial cancer was measured by a direct radioimmunoassay without hydrolysis. The concentration of E1-S in breast cancer tissue was 1.64 +/- 0.28 ng/g wet wt (+/- SE), lower than in surrounding normal breast tissue (4.46 +/- 1.23). Estradiol-17 beta(E2)/E1-S was higher in endometrial cancer tissue than normal endometrial tissue. Estrone sulfatase activity in breast cancer tissue was 0.81 +/- 0.23 nmol/h/mg protein, higher than in surrounding normal breast tissue (0.35 +/- 0.11). These results suggest that E1-S, which is abundant in the peripheral circulation, is hydrolyzed by sulfatase in breast cancer tissue or endometrial cancer tissue and liberates free estrogens, which may stimulate the growth of these malignant tumors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2559248     DOI: 10.1016/0022-4731(89)90408-1

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  11 in total

1.  The effect of adjuvant therapy with or without tamoxifen on the endocrine function of patients with breast cancer.

Authors:  T Yasumura; T Akami; M Mitsuo; T Oka; K Naitoh; T Yamamoto; H Honjyo; H Okada
Journal:  Jpn J Surg       Date:  1990-07

2.  PCOS and obesity: insulin resistance might be a common etiology for the development of type I endometrial carcinoma.

Authors:  Xin Li; Ruijin Shao
Journal:  Am J Cancer Res       Date:  2014-01-15       Impact factor: 6.166

3.  Induction of steroid sulfatase expression by tumor necrosis factor-α through phosphatidylinositol 3-kinase/Akt signaling pathway in PC-3 human prostate cancer cells.

Authors:  Bo Young Suh; Jin Joo Jung; Nahee Park; Cheul Hun Seong; Hee Jung Im; Yeojung Kwon; Donghak Kim; Young Jin Chun
Journal:  Exp Mol Med       Date:  2011-11-30       Impact factor: 8.718

4.  Steroid sulfatase and estrogen sulfotransferase in the atherosclerotic human aorta.

Authors:  Yasuhiro Nakamura; Yasuhiro Miki; Takashi Suzuki; Taisuke Nakata; Andrew David Darnel; Takuya Moriya; Chika Tazawa; Haruo Saito; Tadashi Ishibashi; Shoki Takahashi; Shogo Yamada; Hironobu Sasano
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

5.  Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer.

Authors:  L M Berstein; A E Tchernobrovkina; V B Gamajunova; A J Kovalevskij; D A Vasilyev; O F Chepik; E A Turkevitch; E V Tsyrlina; S J Maximov; L A Ashrafian; J H H Thijssen
Journal:  J Cancer Res Clin Oncol       Date:  2003-04-15       Impact factor: 4.553

6.  Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor Irosustat (STX64, BN83495).

Authors:  L W Lawrence Woo; Dharshini Ganeshapillai; Mark P Thomas; Oliver B Sutcliffe; Bindu Malini; Mary F Mahon; Atul Purohit; Barry V L Potter
Journal:  ChemMedChem       Date:  2011-08-25       Impact factor: 3.466

Review 7.  The Important Roles of Steroid Sulfatase and Sulfotransferases in Gynecological Diseases.

Authors:  Tea Lanišnik Rižner
Journal:  Front Pharmacol       Date:  2016-02-18       Impact factor: 5.810

8.  Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinoma.

Authors:  T R Evans; M G Rowlands; M Law; R C Coombes
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

9.  Oestrone sulphatase activity in mammary tumours and the liver of N-nitrosomethylurea treated rats.

Authors:  T R Evans; S K Chander; M G Rowlands; R C Coombes
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

10.  Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors.

Authors:  Mohammed I El-Gamal; Mohammad H Semreen; Paul A Foster; Barry V L Potter
Journal:  Bioorg Med Chem       Date:  2016-04-22       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.